Hansen Hanne D, Mandeville Joseph B, Sander Christin Y, Hooker Jacob M, Catana Ciprian, Rosen Bruce R, Knudsen Gitte M
Neurobiology Research Unit and NeuroPharm, Copenhagen University Hospital (Rigshospitalet), 2100 Copenhagen, Denmark,
MGH/HST A. A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts 02129, and.
J Neurosci. 2017 Nov 1;37(44):10671-10678. doi: 10.1523/JNEUROSCI.1971-17.2017. Epub 2017 Oct 2.
In the present study, we used a simultaneous PET-MR experimental design to investigate the effects of functionally different compounds (agonist, partial agonist, and antagonist) on 5-HT receptor (5-HTR) occupancy and the associated hemodynamic responses. In anesthetized male nonhuman primates ( = 3), we used positron emission tomography (PET) imaging with the radioligand [C]AZ10419369 administered as a bolus followed by constant infusion to measure changes in 5-HTR occupancy. Simultaneously, we measured changes in cerebral blood volume (CBV) as a proxy of drug effects on neuronal activity. The 5-HTR partial agonist AZ10419369 elicited a dose-dependent biphasic hemodynamic response that was related to the 5-HTR occupancy. The magnitude of the response was spatially overlapping with high cerebral 5-HTR densities. High doses of AZ10419369 exerted an extracranial tissue vasoconstriction that was comparable to the less blood-brain barrier-permeable 5-HTR agonist sumatriptan. By contrast, injection of the antagonist GR127935 did not elicit significant hemodynamic responses, even at a 5-HTR cerebral occupancy similar to the one obtained with a high dose of AZ10419369. Given the knowledge we have of the 5-HTR and its function and distribution in the brain, the hemodynamic response informs us about the functionality of the given drug: changes in CBV are only produced when the receptor is stimulated by the partial agonist AZ10419369 and not by the antagonist GR127935, consistent with low basal occupancy by endogenous serotonin. We here show that combined simultaneous positron emission tomography and magnetic resonance imaging uniquely enables the assessment of CNS active compounds. We conducted a series of pharmacological interventions to interrogate 5-HT receptor binding and function and determined blood-brain barrier passage of drugs and demonstrate target involvement. Importantly, we show how the spatial and temporal effects on brain hemodynamics provide information about pharmacologically driven downstream CNS drug effects; the brain hemodynamic response shows characteristic dose-related effects that differ depending on agonistic or antagonistic drug characteristics and on local 5-HT receptor density. The technique lends itself to a comprehensive investigation and understanding of drugs' effects in the brain.
在本研究中,我们采用同步正电子发射断层扫描-磁共振成像(PET-MR)实验设计,以研究功能不同的化合物(激动剂、部分激动剂和拮抗剂)对5-羟色胺受体(5-HTR)占有率及相关血流动力学反应的影响。在麻醉的雄性非人灵长类动物(n = 3)中,我们使用正电子发射断层扫描(PET)成像,静脉推注放射性配体[C]AZ10419369后持续输注,以测量5-HTR占有率的变化。同时,我们测量脑血容量(CBV)的变化,以此作为药物对神经元活动影响的指标。5-HTR部分激动剂AZ10419369引发了与5-HTR占有率相关的剂量依赖性双相血流动力学反应。该反应的幅度在空间上与高脑5-HTR密度区域重叠。高剂量的AZ10419369引起颅外组织血管收缩,这与血脑屏障通透性较低的5-HTR激动剂舒马曲坦相当。相比之下,注射拮抗剂GR127935即使在5-HTR脑占有率与高剂量AZ10419369所达到的占有率相似时,也未引发显著的血流动力学反应。鉴于我们对5-HTR及其在大脑中的功能和分布的了解,血流动力学反应为我们提供了有关给定药物功能的信息:只有当受体被部分激动剂AZ10419369刺激而非拮抗剂GR127935刺激时,CBV才会发生变化,这与内源性5-羟色胺的低基础占有率一致。我们在此表明,同步正电子发射断层扫描和磁共振成像相结合能够独特地评估中枢神经系统活性化合物。我们进行了一系列药理学干预,以探究5-羟色胺受体的结合和功能,并确定药物的血脑屏障通透性,证明靶点参与情况。重要的是,我们展示了对脑血流动力学的时空效应如何提供有关药理学驱动的中枢神经系统下游药物效应的信息;脑血流动力学反应显示出与剂量相关的特征性效应,这些效应因激动剂或拮抗剂药物特性以及局部5-羟色胺受体密度的不同而有所差异。该技术有助于全面研究和理解药物在大脑中的作用。